Cancer drug prices are rising in the United States and Europe, but European regulators negotiate drug prices, and the results are seen in pricing trends, investigators said in a presentation at the American Society of Clinical Oncology.
Cancer drug costs are rising in both the United States and in Europe, but there are some important differences: US prices start high and go higher. In Europe, launch prices for cancer drugs are typically below those in the United States, and then prices fall after the product is on the market.
The difference? In Europe, regulators negotiate prices, and the United States, they don’t, according to the study authors, led by Kerstin Noelle Vokinger, MD, JD, PhD, LLM, as assistant professor of the University of Zurich who is affiliated with Harvard Medical School.
The findings were presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
“While drug manufacturers set prices without restriction in the United States, European countries have regulations that allow national authorities to directly negotiate drug prices at launch and over time,” the study said.
Investigators tracked prices at launch and over time for 42 solid tumor drugs in this study, and compared pricing in the United States with that of Germany, England, and Switzerland. The study period covered 2009 to 2019.
The average launch prices for monthly treatment costs per patient were $15,178 in the United States versus $7049 in Germany, $7421 in Switzerland, and $8176 in England. Comparing pricing at the interquartile range, (IQR), this meant prices at launch were 215% higher on average in the United States than in Germany; 205% higher on average than Switzerland, and 186% higher on average than England.
Once drugs reached the market, prices went in different directions. Per-month treatment prices decreased over time for 36 drugs in Germany (86%), 40 drugs in Switzerland (95%), and 38 (90%) in England.
However, US monthly treatment costs were more likely to rise after a drug reached the market. “By contrast, prices of 8 (19%) drugs decreased, while 34 (81%) increased post launch in the United States, with total additional expenses of $128,192 for monthly treatment costs.”
In Europe, post-launch price decreases resulted in monthly treatment cost savings of $86,744 in Germany; $44,936, Switzerland; and $1744, England.
“These price disparities continue to increase substantially after market entry since cancer drug prices, in general, decrease over time in Europe and increase in the US,” investigators said.
“Spending on cancer drugs could be reduced in the United States if it adopted the principles used to more effectively negotiate drug prices in Europe,” they noted, adding that the launch prices of cancer drugs have risen more than 100-fold since 1965.
In Europe, they said, national authorities are permitted to directly negotiate drug prices at launch and over time. In the United States, private health payers that provide coverage for Medicare beneficiaries have the power to negotiate Part B drug costs; however, Medicare is prohibited from negotiating drug prices.
For a related story from ASCO20 Virtual on access to cancer drugs and cost, click here. Learn more about ASCO20 Virtual by visiting our conference page.
Reference
Vokinger KN, Daniore P, Lee CWC, et al. Launch prices and price developments of cancer drugs in the United States and Europe. J Clin Oncol 2020;38(suppl; abstr 2006): doi: 10.1200/JCO.2020.38.15_suppl.2006
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.